Sign Out
If any of the conditions or risk factors mentioned as follows is present, the suitability of Nextstellis should be discussed with the woman before she decides to start using Nextstellis.
In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Nextstellis should be discontinued. All data presented as follows are based upon epidemiological data obtained with CHCs containing ethinylestradiol. Nextstellis contains estetrol. As no epidemiological data are yet available with estetrol containing-CHCs, the warnings are considered applicable to the use of Nextstellis.
In case of suspected or confirmed VTE or ATE, CHC use must be discontinued. In case anticoagulant therapy is started, adequate alternative non-hormonal contraception should be initiated because of the teratogenicity of anticoagulant therapy (coumarins).
